FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201656368> ?p ?o ?g. }

• W3201656368 endingPage "e210048" @default.
• W3201656368 startingPage "e210048" @default.
• W3201656368 abstract "Purpose To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, including molecular characteristics. Materials and Methods In this observational, prospective study, participants were recruited from November 2015 to March 2018 who had a diagnosis of myeloma, who were planned to undergo chemotherapy and autologous stem cell transplantation, and who underwent baseline WB-MRI and FDG PET/CT (ClinicalTrials.gov identifier NCT02403102). Baseline clinical data, including genetics, were collected. Paired methods were used to compare burden and patterns of disease. Results Sixty participants (mean age, 60 years ± 9 [standard deviation]; 35 men) underwent baseline WB-MRI and FDG PET/CT. WB-MRI showed significantly higher detection for focal lesions at all anatomic sites (except ribs, scapulae, and clavicles) and for diffuse disease at all sites. Two participants presented with two or more focal lesions smaller than 5 mm only at WB-MRI but not FDG PET/CT. Participants with diffuse disease at MRI had higher plasma cell infiltration (percentage of nucleated cells: median, 60% [interquartile range {IQR}, 50%–61%] vs 15% [IQR, 4%–50%]; P = .03) and paraprotein levels (median, 32.0 g/L [IQR, 24.0–48.0 g/L] vs 20.0 g/L [IQR, 12.0–22.6 g/L]; P = .02) compared with those without diffuse disease. All genetically high-risk tumors showed diffuse infiltration at WB-MRI. Conclusion WB-MRI helped detect a higher number of myeloma lesions than FDG PET/CT, and diffuse disease detected at WB-MRI correlated with laboratory measures of disease burden and molecular markers of risk. Keywords: MR-Imaging, Skeletal-Appendicular, Skeletal-Axial, Bone Marrow, Hematologic Diseases, Oncology Clinical trial registration no. NCT02403102. Supplemental material is available for this article. Published under a CC BY 4.0 license." @default.
• W3201656368 created "2021-09-27" @default.
• W3201656368 creator A5002276697 @default.
• W3201656368 creator A5011198932 @default.
• W3201656368 creator A5013749352 @default.
• W3201656368 creator A5015884438 @default.
• W3201656368 creator A5016899907 @default.
• W3201656368 creator A5019134004 @default.
• W3201656368 creator A5019506055 @default.
• W3201656368 creator A5019572933 @default.
• W3201656368 creator A5022609560 @default.
• W3201656368 creator A5028997092 @default.
• W3201656368 creator A5036393520 @default.
• W3201656368 creator A5040106089 @default.
• W3201656368 creator A5048179253 @default.
• W3201656368 creator A5051776381 @default.
• W3201656368 creator A5061550633 @default.
• W3201656368 creator A5070554692 @default.
• W3201656368 creator A5072977279 @default.
• W3201656368 creator A5073477610 @default.
• W3201656368 creator A5074540413 @default.
• W3201656368 date "2021-09-01" @default.
• W3201656368 modified "2023-10-16" @default.
• W3201656368 title "Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma" @default.
• W3201656368 cites W1823421108 @default.
• W3201656368 cites W1964471413 @default.
• W3201656368 cites W1968121313 @default.
• W3201656368 cites W1976919663 @default.
• W3201656368 cites W2031907348 @default.
• W3201656368 cites W2044436186 @default.
• W3201656368 cites W2058282285 @default.
• W3201656368 cites W2073370692 @default.
• W3201656368 cites W2096672426 @default.
• W3201656368 cites W2097434381 @default.
• W3201656368 cites W2131900456 @default.
• W3201656368 cites W2144728882 @default.
• W3201656368 cites W2144930991 @default.
• W3201656368 cites W2158152463 @default.
• W3201656368 cites W2158749770 @default.
• W3201656368 cites W2163480869 @default.
• W3201656368 cites W2168065936 @default.
• W3201656368 cites W2296484123 @default.
• W3201656368 cites W2318069817 @default.
• W3201656368 cites W2415257442 @default.
• W3201656368 cites W2508338040 @default.
• W3201656368 cites W2591651461 @default.
• W3201656368 cites W2607239695 @default.
• W3201656368 cites W2724736336 @default.
• W3201656368 cites W2744373774 @default.
• W3201656368 cites W2916571767 @default.
• W3201656368 cites W2933753081 @default.
• W3201656368 cites W2947708728 @default.
• W3201656368 cites W2948900997 @default.
• W3201656368 cites W2953595774 @default.
• W3201656368 cites W2955260405 @default.
• W3201656368 cites W2989715662 @default.
• W3201656368 cites W2996738172 @default.
• W3201656368 cites W3014125522 @default.
• W3201656368 cites W3031307739 @default.
• W3201656368 cites W3035218788 @default.
• W3201656368 cites W3040296587 @default.
• W3201656368 cites W3095212330 @default.
• W3201656368 cites W3121354053 @default.
• W3201656368 doi "https://doi.org/10.1148/rycan.2021210048" @default.
• W3201656368 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8489453" @default.
• W3201656368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34559006" @default.
• W3201656368 hasPublicationYear "2021" @default.
• W3201656368 type Work @default.
• W3201656368 sameAs 3201656368 @default.
• W3201656368 citedByCount "16" @default.
• W3201656368 countsByYear W32016563682022 @default.
• W3201656368 countsByYear W32016563682023 @default.
• W3201656368 crossrefType "journal-article" @default.
• W3201656368 hasAuthorship W3201656368A5002276697 @default.
• W3201656368 hasAuthorship W3201656368A5011198932 @default.
• W3201656368 hasAuthorship W3201656368A5013749352 @default.
• W3201656368 hasAuthorship W3201656368A5015884438 @default.
• W3201656368 hasAuthorship W3201656368A5016899907 @default.
• W3201656368 hasAuthorship W3201656368A5019134004 @default.
• W3201656368 hasAuthorship W3201656368A5019506055 @default.
• W3201656368 hasAuthorship W3201656368A5019572933 @default.
• W3201656368 hasAuthorship W3201656368A5022609560 @default.
• W3201656368 hasAuthorship W3201656368A5028997092 @default.
• W3201656368 hasAuthorship W3201656368A5036393520 @default.
• W3201656368 hasAuthorship W3201656368A5040106089 @default.
• W3201656368 hasAuthorship W3201656368A5048179253 @default.
• W3201656368 hasAuthorship W3201656368A5051776381 @default.
• W3201656368 hasAuthorship W3201656368A5061550633 @default.
• W3201656368 hasAuthorship W3201656368A5070554692 @default.
• W3201656368 hasAuthorship W3201656368A5072977279 @default.
• W3201656368 hasAuthorship W3201656368A5073477610 @default.
• W3201656368 hasAuthorship W3201656368A5074540413 @default.
• W3201656368 hasBestOaLocation W32016563681 @default.
• W3201656368 hasConcept C119060515 @default.
• W3201656368 hasConcept C126322002 @default.
• W3201656368 hasConcept C126838900 @default.
• W3201656368 hasConcept C127077266 @default.
• W3201656368 hasConcept C142724271 @default.

• next